News

InSphero announces winners of HUMAIN Award 2025

Schlieren, Switzerland and Washington, D.C. — The Schlieren-based biotech company InSphero is presenting the HUMAIN Award for the second time this year, in collaboration with the Physicians Committee for Responsible Medicine. The five winning teams are from Switzerland, Portugal, the United States, Spain, and Germany. According to a press release, InSphero...

read more

ImmunOs Therapeutics Reports Promising Clinical Activity of IOS-1002 in Advanced Solid Tumors

Schlieren, Switzerland, October 20, 2025 – ImmunOs Therapeutics AG, a clinical-stage biopharmaceutical company leveraging its unique immune system modulating HLA-based technology platform to develop first-in-class therapeutics for the treatment of cancer and inflammatory diseases, today announced encouraging preliminary results from its ongoing Phase I clinical trial evaluating IOS-1002 in patients with advanced...

read more

Neurimmune begins phase 2 trial treatment

Zurich, Switzerland - 14.10.2025 Neurimmune today announced it has initiated a Phase 2 follow-on study to evaluate the pharmacodynamics and safety of cliramitug (formerly ALXN2220, NI006) for transthyretin amyloid cardiomyopathy (ATTR-CM) in patients who were previously enrolled in the proof-of-concept study NI006-101 (NCT04360434). Cliramitug is an investigational human monoclonal antibody designed to...

read more

Kuros Biosciences Inaugurates New US Site

Schlieren, ZH/Alpharetta — Kuros Biosciences AG, based in Schlieren, marks the first step toward commissioning a new plant in the US with a symbolic ribbon-cutting ceremony. The official opening will follow in July 2026. According to a press release, Kuros Biosciences took the "first step" in its US expansion by cutting...

read more